Developer docs
API playgroundTry for free, no card

Search company profiles

BIOCODEX

Full company profile

uuid000594h

Namestring
BIOCODEX
Legal namestring
BIOCODEX
Websiteurl
biocodex.fr
Company typeenum
Private
Founded yearint
1953
Descriptiontext

BIOCODEX is a privately held, family-founded French multinational pharmaceutical company established in 1953 and headquartered in Gentilly, France. The company operates across five therapeutic areas — microbiota, women's health, mental health, rare diseases, and established products/family health — with a diversified portfolio spanning prescription medications, medical devices, food supplements, dermo-cosmetics, and intimate care products. Its core technological foundation is the Saccharomyces boulardii CNCM I-745 strain, the world's first probiotic yeast commercialized globally since 1923 and deposited at the Institut Pasteur, supplemented by proprietary strains including Bifidobacterium longum 35624 (via PrecisionBiotics partnership), patent-protected Lactobacillus crispatus IP174178, and Bacillus coagulans/subtilis formulations. The company maintains vertically integrated manufacturing at its Beauvais facility and operates 16 wholly-owned subsidiaries and 100+ distribution partners across Africa, the Americas, Asia, and Europe, reaching 15+ countries for flagship brands.

BIOCODEX generates revenue through diversified product sales across consumer health, women's health, and pharmaceutical categories, distributed primarily through pharmacy and parapharmacy networks. The company reported EUR 677 million in revenue for fiscal year 2025 with a workforce of 1,900+ employees representing 40+ nationalities. Its go-to-market combines enterprise field sales targeting healthcare professionals (physicians, pharmacists, specialists) with consumer-facing brand marketing across dedicated product websites. Key sub-brands include SYMBIOSYS (probiotics including Alflorex+, Stomalex, Ultra-Protect ATB), THALAMAG (marine magnesium supplements with 30+ years of heritage), Saforelle (intimate care created 1989), Gestarelle (maternity, 30+ years), and Rap Phyto (circulation, 100 years of expertise). The company recently expanded into rare disease therapeutics through a strategic licensing agreement with THX Pharma (up to EUR 173 million in potential deal value for Batten-1 and TX01 treatments) and maintains a nine-year strategic partnership with PrecisionBiotics (Novonesis) for microbiome science collaboration. Additional revenue streams include licensing royalties from rare disease drug development. BIOCODEX holds family ownership with no disclosed external investors, subsidiaries including IPRAD PHARMA and Phardex, and holds certifications including AFNOR ISO 26000 and a Gender Equality Index score of 97/100.

Short descriptiontext

BIOCODEX is a privately held French multinational pharmaceutical company founded in 1953 that develops and distributes probiotic, women's health, mental health, rare disease, and family health products across 15+ countries through 16 subsidiaries and 100+ distribution partners, reporting EUR 677M in 2025 revenue.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersGentilly, France
HQ citystring
Gentilly
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical products, probiotic supplements, microbiota therapeutics, women's health products, rare disease treatments
Industry2 codes
PRIMARYHLAAAFAJ
Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery)
SECONDARYEUAAAIAK
Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Microbiota Pharmaceuticals
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Pharmaceutical products
TypeOne Time License
Description

Prescription and over-the-counter medications including established products for gastroenterology, pain management, and ORL conditions. Revenue from drug formulations and medications.

biocodex.fr
2Dietary supplements
TypeOne Time License
Description

Non-prescription supplements including probiotics (SYMBIOSYS, Alflorex+, ULTRA-PROTECT), magnesium-based products (THALAMAG), and specialized formulations for women's health (Gestarelle) and family health.

biocodex.fr
3Medical devices
TypeOne Time License
Description

Medical devices including intimate care products (Saforelle Mucogyne ovules and gel) and dermo-cosmetics for women's intimate health.

biocodex.fr
4Rare disease drug licensing
TypeLicensing Royalties
Description

Licensing and commercialization rights for rare disease treatments (Batten-1, TX01) through partnership with THX Pharma, valued at up to EUR 173 million including upfront and milestone payments plus royalties.

biocodex.fr
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain
Pricing details1 tier
1Canadian National Research Grant for microbiota research
ModelOtherBilling cadenceAnnual
Notes

EUR 35,000 (approximately CAD $55,000) grant for one researcher at Canadian university/research institution for 1-2 year microbiota research projects

financialpost.com
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 14 records shown
1Saforelle
Description

Intimate hygiene and care product line for women

biocodex.fr
+13 more records
Core offering1 text field

Biocodex develops, manufactures, and commercializes pharmaceutical products, dietary supplements, medical devices, and dermo-cosmetics built on microbiome science. Its portfolio spans five therapeutic areas — microbiota, women's health, mental health, rare diseases, and family health/established products — distributed through pharmacy and parapharmacy networks, 16 subsidiaries, and 100+ distribution partners across more than 15 countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Alflorex available in 15+ countries through PrecisionBiotics partnership
+3 more records
Product overview1 text field

Biocodex is a multinational pharmaceutical company with a diversified portfolio organized around five therapeutic areas: Microbiota, Women's Health, Mental Health, Rare Diseases, and Established Products & Family Health. The core probiotic heritage stems from Saccharomyces boulardii CNCM I-745, the world's first probiotic yeast strain commercialized over 70 years ago. The product portfolio spans prescription medicines, medical devices (vaginal ovules and gels), food supplements (probiotics, magnesium, circulation, maternity), dermo-cosmetics, and intimate care products. Key sub-brands include SYMBIOSYS (probiotics including Alflorex+, Stomalex, Ultra-Protect ATB), THALAMAG (marine magnesium supplements), Saforelle (intimate care with Mucogyne and Physioflor sub-lines), Gestarelle (maternity), and Rap Phyto (leg circulation). The company operates 16 subsidiaries and 100 distribution partners globally with 2025 revenue of €677 million.

Product and service24 records
1SYMBIOSYS Alflorex+
CategoryProbiotic Supplements
Description

Probiotic supplement containing the proprietary Bifidobacterium longum 35624 strain, isolated from healthy human intestines, designed to restore intestinal flora balance and digestive comfort. Developed in partnership with PrecisionBiotics and APC Microbiome Ireland.

2SYMBIOSYS Stomalex
CategoryProbiotic Supplements
Description

Probiotic supplement combining Bacillus coagulans MY-01 and Bacillus subtilis MY-02 strains with ginger extract to support intestinal flora balance and normal stomach function.

3ULTRA-PROTECT ATB
CategoryProbiotic Supplements
Description

Food supplement for special medical purposes containing the Saccharomyces boulardii CNCM I-745 probiotic strain, zinc, vitamin C, and vitamin D3 to support immune function and intestinal flora balance during antibiotic treatment.

4Saforelle Mucogyne Ovules
CategoryWomen's Intimate Care
Description

Non-hormonal vaginal ovules based on hyaluronic acid for restoring vaginal mucosa, promoting cellular repair, maintaining hydration, and supporting natural pH balance. CE marked medical device.

5Saforelle Mucogyne Gel
CategoryWomen's Intimate Care
Description

Non-hormonal intimate gel with liposomal hyaluronic acid for restoring vulvovaginal mucosa, providing lubrication, hydration, and flexibility for intimate comfort.

6Saforelle Mucogyne Voie Orale
CategoryWomen's Intimate Care
Description

Food supplement with ExceptionHYAL hyaluronic acid complex, vitamin B8 for mucosal maintenance, and wheat ceramides for skin elasticity support in intimate care.

7Saforelle Physioflor Oral
CategoryWomen's Intimate Care
Description

First food supplement for intimate flora composed of 100% Lactobacillus crispatus, a patented probiotic strain supporting vaginal health.

8Physioflor AC
CategoryWomen's Intimate Care
Description

Medical device - acidifying vaginal gel containing lactic acid, glycerol, and alpha-glucan oligosaccharides for treating bacterial vaginosis symptoms and preventing recurrence.

9Gestarelle G+
CategoryMaternity Nutrition
Description

Prenatal supplement recommended from pre-conception through pregnancy and breastfeeding, providing essential vitamins, folic acid (Quatrefolic), iron, iodine, vitamin D, and Omega-3 for fetal development.

10Gestarelle Fertilité
CategoryMaternity Nutrition
Description

Preconception supplement combining zinc for normal fertility, selenium for immune protection, iodine for thyroid function, and vitamin B9 (Quatrefolic) for neural tube defect prevention.

11Gestarelle Huile Vergetures Maternité
CategoryMaternity Skincare
Description

Bio stretch mark oil with sweet almond oil, Centella asiatica extract, and vitamin E for preventing stretch marks and improving skin elasticity during pregnancy.

12THALAMAG Equilibre Intérieur LP
CategoryMagnesium Supplements
Description

Marine magnesium supplement from the Irish Sea using Sepismart SR technology for extended release, providing 300mg of magnesium per day to reduce fatigue and support nervous system function.

13THALAMAG Boost
CategoryMagnesium Supplements
Description

Energy and tonicity supplement combining marine magnesium with cola nut and spirulina for sustained energy support.

14THALAMAG Immunité
CategoryMagnesium Supplements
Description

Immune support supplement with marine magnesium from the Irish Sea, iron, and folate (vitamin B9) contributing to normal immune system function.

15THALAMAG Plasma Marin
CategoryMagnesium Supplements
Description

Marine plasma supplement based on René Quinton's discovery, combining seawater with magnesium and selenium for fatigue reduction and immune function support.

16MYLEUCA
CategoryBody Hygiene
Description

Cleansing body wash solution with Tea Tree (Melaleuca alternifolia) oil for sensitive skin prone to cutaneous mycosis, with a gentle alkaline pH of 8.5.

17DE(RAMP) Comprimés
CategoryMuscle Relaxation
Description

Food supplement for normal muscle function containing magnesium, potassium, and copper to support muscle recovery and energy metabolism.

18DE(RAMP) Gel
CategoryMuscle Relaxation
Description

Muscle comfort gel with Wintergreen essential oil, Arnica montana extract, and menthol for a cooling and relaxing effect on tired muscles.

19Rap Phyto Crème Apaisante
CategoryCirculation and Leg Comfort
Description

N°1 leg lighter cream formulated with natural ingredients including horse chestnut, broom flower, and Arnica montana for relieving and toning tired legs.

20Rap Phyto Gel Fraîcheur Menthol
CategoryCirculation and Leg Comfort
Description

Certified bio cooling gel with menthol and natural active ingredients for instant and prolonged cooling sensation to relieve tired legs.

21Rap Phyto Gel Fraîcheur Agrumes
CategoryCirculation and Leg Comfort
Description

Certified bio citrus-scented cooling gel providing instant freshness and toning effect for fatigued legs.

22Rap Phyto Jambes Légères
CategoryCirculation and Leg Comfort
Description

Food supplement with horse chestnut extract and blackcurrant for normal venous circulation, combined with vitamin C for normal blood vessel function.

23DIFRAVISION
CategoryEye Health Supplements
Description

Food supplement with blueberry extract, vitamins C and E, zinc, selenium, DHA, lutein, and zeaxanthine for vision health and cellular protection against oxidative stress.

24Batten-1 (licensed rare disease treatment)
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-23
Description

Nine-year strategic partnership formalized at leadership meeting in Copenhagen for microbiome science and consumer health. Expansion of scientific collaboration and market reach for flagship product Alflorex, now available in over 15 countries. New agreement expected to accelerate growth by deepening scientific collaboration and unlocking new market opportunities. Novonesis formed from Chr. Hansen-Novozymes merger.

2THX Pharma (Theranexus)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-11
Description

Strategic licensing agreement for development and commercialization of treatments for three rare diseases. Biocodex acquired exclusive worldwide rights for Batten-1 (juvenile Batten disease) and exclusive US/Canada rights for TX01 (Gaucher and Niemann-Pick type C diseases). Deal valued at up to EUR 173 million including EUR 12 million upfront, milestone payments, and tiered double-digit royalties. THX Pharma leads clinical development while Biocodex handles compassionate use, market access, and commercialization. Phase 3 trial for Batten-1 planned for 2026 with international launch targeted around 2030.

pharmatimes.com
Strategic tierMinorTypeOthers
Description

Corporate foundation funded by Biocodex supporting microbiota research. Opens annual applications for EUR 35,000 research grant to Canadian academics and scientists for microbiota-related research projects lasting 1-2 years. 2026 applications due October 30, with selection announced November 30. 2025 recipient was Dr. Xiaopeng Bai from McMaster University for stress-microbiota-intestinal barrier axis research.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global leader in microbial and fermentation solutions with a dedicated Health & Nutrition probiotics business (formerly Chr. Hansen). Directly comparable as a microbiome/probiotic platform serving consumer health and pharma customers, and Biocodex's stated strategic partner through PrecisionBiotics.

2BioGaia
TypeDirect peer
Description

Swedish probiotics specialist selling clinically documented Lactobacillus and Bifidobacterium strains via OTC, pharmacy, and prescription channels. Highly comparable to Biocodex in business model (proprietary probiotic strains, pharma distribution, women's and gut health focus) though smaller in scale.

3Lallemand Health Solutions
TypeDirect peer
Description

Canadian probiotic manufacturer producing proprietary yeast (Saccharomyces boulardii) and bacterial strains for pharma and supplement brands globally. Directly competes with Biocodex in the probiotic strain and formulation space and serves overlapping B2B and branded customers.

TypeDirect peer
Description

Swedish probiotic R&D and B2B supplier with clinically validated Lactobacillus plantarum strains licensed to consumer health and pharma brands. Comparable as a science-led probiotic platform serving similar end-markets (gut health, women's health, immune support).

TypeBroad incumbent
Description

Japanese multinational built around a proprietary Lactobacillus casei Shirota strain with global distribution in probiotic dairy and supplements. Comparable as a globally scaled, single-strain probiotic franchise, though delivery vehicle is primarily fermented dairy rather than supplements.

TypeBroad incumbent
Description

Global food and nutrition major with large probiotic and microbiome exposure (Activia, Actimel, medical nutrition brands). Comparable in end-market overlap (digestive health, women's health, infant nutrition) but operates at vastly larger scale and broader portfolio than Biocodex.

TypeRegional player
Description

French privately held pharmaceutical and dermo-cosmetic group with strong pharmacy-channel presence in women's health, dermatology, and consumer health. Highly comparable as a French independent pharma peer with similar pharmacy distribution model, family-ownership heritage, and women's health focus.

8Bayer Consumer Health
TypeBroad incumbent
Description

Division of Bayer selling OTC pharma, probiotics, and women's health brands globally through pharmacy and mass retail. Comparable in target categories (women's health, gut health, OTC pharma) though it operates across a much broader portfolio and larger geographic footprint.

TypeBroad incumbent
Description

French-headquartered global pharmaceutical major with a dedicated Consumer Healthcare business spanning women's health, digestive health, and probiotics. Comparable in target therapeutic areas and pharmacy-channel GTM, though at much larger scale and with broader R&D capabilities.

TypeEmerging player
Description

French clinical-stage biotech developing treatments for rare neurological diseases including Batten-1 and TX01. Biocodex is its licensing partner and exclusive worldwide commercialization partner for these assets, making it a directly relevant biotech counterpart in the rare disease pipeline.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BIOCODEX

Microbiota Pharmaceuticalsbiocodex.fr

BIOCODEX is a privately held French multinational pharmaceutical company founded in 1953 that develops and distributes probiotic, women's health, mental health, rare disease, and family health products across 15+ countries through 16 subsidiaries and 100+ distribution partners, reporting EUR 677M in 2025 revenue.

What BIOCODEX does

BIOCODEX is a privately held, family-founded French multinational pharmaceutical company established in 1953 and headquartered in Gentilly, France. The company operates across five therapeutic areas — microbiota, women's health, mental health, rare diseases, and established products/family health — with a diversified portfolio spanning prescription medications, medical devices, food supplements, dermo-cosmetics, and intimate care products. Its core technological foundation is the Saccharomyces boulardii CNCM I-745 strain, the world's first probiotic yeast commercialized globally since 1923 and deposited at the Institut Pasteur, supplemented by proprietary strains including Bifidobacterium longum 35624 (via PrecisionBiotics partnership), patent-protected Lactobacillus crispatus IP174178, and Bacillus coagulans/subtilis formulations. The company maintains vertically integrated manufacturing at its Beauvais facility and operates 16 wholly-owned subsidiaries and 100+ distribution partners across Africa, the Americas, Asia, and Europe, reaching 15+ countries for flagship brands.

BIOCODEX generates revenue through diversified product sales across consumer health, women's health, and pharmaceutical categories, distributed primarily through pharmacy and parapharmacy networks. The company reported EUR 677 million in revenue for fiscal year 2025 with a workforce of 1,900+ employees representing 40+ nationalities. Its go-to-market combines enterprise field sales targeting healthcare professionals (physicians, pharmacists, specialists) with consumer-facing brand marketing across dedicated product websites. Key sub-brands include SYMBIOSYS (probiotics including Alflorex+, Stomalex, Ultra-Protect ATB), THALAMAG (marine magnesium supplements with 30+ years of heritage), Saforelle (intimate care created 1989), Gestarelle (maternity, 30+ years), and Rap Phyto (circulation, 100 years of expertise). The company recently expanded into rare disease therapeutics through a strategic licensing agreement with THX Pharma (up to EUR 173 million in potential deal value for Batten-1 and TX01 treatments) and maintains a nine-year strategic partnership with PrecisionBiotics (Novonesis) for microbiome science collaboration. Additional revenue streams include licensing royalties from rare disease drug development. BIOCODEX holds family ownership with no disclosed external investors, subsidiaries including IPRAD PHARMA and Phardex, and holds certifications including AFNOR ISO 26000 and a Gender Equality Index score of 97/100.

BIOCODEX firmographics

Firmographics
Name
BIOCODEX
Legal name
BIOCODEX
Website
https://biocodex.fr
Company type
Private
Founded year
1953
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
BIOCODEX is a privately held French multinational pharmaceutical company founded in 1953 that develops and distributes probiotic, women's health, mental health, rare disease, and family health products across 15+ countries through 16 subsidiaries and 100+ distribution partners, reporting EUR 677M in 2025 revenue.
Ownership category
akta.pro rank

BIOCODEX industry classification

Industry
Product category
Microbiota Pharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAFAJ
Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery)
SECONDARYEUAAAIAK
Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)

Keywords

  • Pharmaceutical products
  • Probiotic supplements
  • Microbiota therapeutics
  • Women's health products
  • Rare disease treatments

Where BIOCODEX is headquartered

Location

Headquarters

HQ city
Gentilly
HQ country
France
HQ region
Europe

Offices4 records

Markets served

BIOCODEX business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

  1. Pharmaceutical products: Prescription and over-the-counter medications including established products for gastroenterology, pain management, and ORL conditions. Revenue from drug formulations and medications.
  2. Dietary supplements: Non-prescription supplements including probiotics (SYMBIOSYS, Alflorex+, ULTRA-PROTECT), magnesium-based products (THALAMAG), and specialized formulations for women's health (Gestarelle) and family health.
  3. Medical devices: Medical devices including intimate care products (Saforelle Mucogyne ovules and gel) and dermo-cosmetics for women's intimate health.
  4. Rare disease drug licensing: Licensing and commercialization rights for rare disease treatments (Batten-1, TX01) through partnership with THX Pharma, valued at up to EUR 173 million including upfront and milestone payments plus royalties.

Pricing tiers

ModelBillingPrice
OtherAnnualCanadian National Research Grant for microbiota research

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

BIOCODEX product offering

Product offering

Core offering

Biocodex develops, manufactures, and commercializes pharmaceutical products, dietary supplements, medical devices, and dermo-cosmetics built on microbiome science. Its portfolio spans five therapeutic areas — microbiota, women's health, mental health, rare diseases, and family health/established products — distributed through pharmacy and parapharmacy networks, 16 subsidiaries, and 100+ distribution partners across more than 15 countries.

Product overview

Biocodex is a multinational pharmaceutical company with a diversified portfolio organized around five therapeutic areas: Microbiota, Women's Health, Mental Health, Rare Diseases, and Established Products & Family Health. The core probiotic heritage stems from Saccharomyces boulardii CNCM I-745, the world's first probiotic yeast strain commercialized over 70 years ago. The product portfolio spans prescription medicines, medical devices (vaginal ovules and gels), food supplements (probiotics, magnesium, circulation, maternity), dermo-cosmetics, and intimate care products. Key sub-brands include SYMBIOSYS (probiotics including Alflorex+, Stomalex, Ultra-Protect ATB), THALAMAG (marine magnesium supplements), Saforelle (intimate care with Mucogyne and Physioflor sub-lines), Gestarelle (maternity), and Rap Phyto (leg circulation). The company operates 16 subsidiaries and 100 distribution partners globally with 2025 revenue of €677 million.

Differentiator

Problem solved

Functional benefit

Brands

  • Saforelle: Intimate hygiene and care product line for women
  • Gestarelle
  • Rap Phyto
  • Thalamag
  • Myleuca
  • DE(RAMP)
  • SYMBIOSYS
  • SYMBIOSYS ALFLOREX+
  • ULTRA-PROTECT ATB
  • SYMBIOSYS STOMALEX
  • DIFRAVISION
  • Saforelle Mucogyne
  • Physioflor
  • Biocodex Microbiota Foundation

Products and services

  • SYMBIOSYS Alflorex+ Probiotic supplement containing the proprietary Bifidobacterium longum 35624 strain, isolated from healthy human intestines, designed to restore intestinal flora balance and digestive comfort. Developed in partnership with PrecisionBiotics and APC Microbiome Ireland.
  • SYMBIOSYS Stomalex Probiotic supplement combining Bacillus coagulans MY-01 and Bacillus subtilis MY-02 strains with ginger extract to support intestinal flora balance and normal stomach function.
  • ULTRA-PROTECT ATB Food supplement for special medical purposes containing the Saccharomyces boulardii CNCM I-745 probiotic strain, zinc, vitamin C, and vitamin D3 to support immune function and intestinal flora balance during antibiotic treatment.
  • Saforelle Mucogyne Ovules Non-hormonal vaginal ovules based on hyaluronic acid for restoring vaginal mucosa, promoting cellular repair, maintaining hydration, and supporting natural pH balance. CE marked medical device.
  • Saforelle Mucogyne Gel Non-hormonal intimate gel with liposomal hyaluronic acid for restoring vulvovaginal mucosa, providing lubrication, hydration, and flexibility for intimate comfort.
  • Saforelle Mucogyne Voie Orale Food supplement with ExceptionHYAL hyaluronic acid complex, vitamin B8 for mucosal maintenance, and wheat ceramides for skin elasticity support in intimate care.
  • Saforelle Physioflor Oral First food supplement for intimate flora composed of 100% Lactobacillus crispatus, a patented probiotic strain supporting vaginal health.
  • Physioflor AC Medical device - acidifying vaginal gel containing lactic acid, glycerol, and alpha-glucan oligosaccharides for treating bacterial vaginosis symptoms and preventing recurrence.
  • Gestarelle G+ Prenatal supplement recommended from pre-conception through pregnancy and breastfeeding, providing essential vitamins, folic acid (Quatrefolic), iron, iodine, vitamin D, and Omega-3 for fetal development.
  • Gestarelle Fertilité Preconception supplement combining zinc for normal fertility, selenium for immune protection, iodine for thyroid function, and vitamin B9 (Quatrefolic) for neural tube defect prevention.
  • Gestarelle Huile Vergetures Maternité Bio stretch mark oil with sweet almond oil, Centella asiatica extract, and vitamin E for preventing stretch marks and improving skin elasticity during pregnancy.
  • THALAMAG Equilibre Intérieur LP Marine magnesium supplement from the Irish Sea using Sepismart SR technology for extended release, providing 300mg of magnesium per day to reduce fatigue and support nervous system function.
  • THALAMAG Boost Energy and tonicity supplement combining marine magnesium with cola nut and spirulina for sustained energy support.
  • THALAMAG Immunité Immune support supplement with marine magnesium from the Irish Sea, iron, and folate (vitamin B9) contributing to normal immune system function.
  • THALAMAG Plasma Marin Marine plasma supplement based on René Quinton's discovery, combining seawater with magnesium and selenium for fatigue reduction and immune function support.
  • MYLEUCA Cleansing body wash solution with Tea Tree (Melaleuca alternifolia) oil for sensitive skin prone to cutaneous mycosis, with a gentle alkaline pH of 8.5.
  • DE(RAMP) Comprimés Food supplement for normal muscle function containing magnesium, potassium, and copper to support muscle recovery and energy metabolism.
  • DE(RAMP) Gel Muscle comfort gel with Wintergreen essential oil, Arnica montana extract, and menthol for a cooling and relaxing effect on tired muscles.
  • Rap Phyto Crème Apaisante N°1 leg lighter cream formulated with natural ingredients including horse chestnut, broom flower, and Arnica montana for relieving and toning tired legs.
  • Rap Phyto Gel Fraîcheur Menthol Certified bio cooling gel with menthol and natural active ingredients for instant and prolonged cooling sensation to relieve tired legs.
  • Rap Phyto Gel Fraîcheur Agrumes Certified bio citrus-scented cooling gel providing instant freshness and toning effect for fatigued legs.
  • Rap Phyto Jambes Légères Food supplement with horse chestnut extract and blackcurrant for normal venous circulation, combined with vitamin C for normal blood vessel function.
  • DIFRAVISION Food supplement with blueberry extract, vitamins C and E, zinc, selenium, DHA, lutein, and zeaxanthine for vision health and cellular protection against oxidative stress.
  • Batten-1 (licensed rare disease treatment)

Quantifiable outcome

  • Alflorex available in 15+ countries through PrecisionBiotics partnership
  • +3 more outcomes

Companies that use BIOCODEX

Customer profile

Named customers1 record

Segments5 records

Ideal customer profiles5 records

BIOCODEX technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

BIOCODEX partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • PrecisionBiotics (Novonesis)coreStrategic or Co-development Partner · 23 April 2026Nine-year strategic partnership formalized at leadership meeting in Copenhagen for microbiome science and consumer health. Expansion of scientific collaboration and market reach for flagship product Alflorex, now available in over 15 countries. New agreement expected to accelerate growth by deepening scientific collaboration and unlocking new market opportunities. Novonesis formed from Chr. Hansen-Novozymes merger.
  • THX Pharma (Theranexus)coreStrategic or Co-development Partner · 11 February 2026Strategic licensing agreement for development and commercialization of treatments for three rare diseases. Biocodex acquired exclusive worldwide rights for Batten-1 (juvenile Batten disease) and exclusive US/Canada rights for TX01 (Gaucher and Niemann-Pick type C diseases). Deal valued at up to EUR 173 million including EUR 12 million upfront, milestone payments, and tiered double-digit royalties. THX Pharma leads clinical development while Biocodex handles compassionate use, market access, and commercialization. Phase 3 trial for Batten-1 planned for 2026 with international launch targeted around 2030.
  • Biocodex Microbiota FoundationminorOthersCorporate foundation funded by Biocodex supporting microbiota research. Opens annual applications for EUR 35,000 research grant to Canadian academics and scientists for microbiota-related research projects lasting 1-2 years. 2026 applications due October 30, with selection announced November 30. 2025 recipient was Dr. Xiaopeng Bai from McMaster University for stress-microbiota-intestinal barrier axis research.

Scale indicators11 records

Recent moves6 records

Expansion highlights5 records

BIOCODEX competitors and assessment

Company assessment

Direct peers

  • Novonesis (Chr. Hansen): Global leader in microbial and fermentation solutions with a dedicated Health & Nutrition probiotics business (formerly Chr. Hansen). Directly comparable as a microbiome/probiotic platform serving consumer health and pharma customers, and Biocodex's stated strategic partner through PrecisionBiotics.
  • BioGaia: Swedish probiotics specialist selling clinically documented Lactobacillus and Bifidobacterium strains via OTC, pharmacy, and prescription channels. Highly comparable to Biocodex in business model (proprietary probiotic strains, pharma distribution, women's and gut health focus) though smaller in scale.
  • Lallemand Health Solutions: Canadian probiotic manufacturer producing proprietary yeast (Saccharomyces boulardii) and bacterial strains for pharma and supplement brands globally. Directly competes with Biocodex in the probiotic strain and formulation space and serves overlapping B2B and branded customers.
  • Probi: Swedish probiotic R&D and B2B supplier with clinically validated Lactobacillus plantarum strains licensed to consumer health and pharma brands. Comparable as a science-led probiotic platform serving similar end-markets (gut health, women's health, immune support).

Broad incumbents

  • Yakult Honsha: Japanese multinational built around a proprietary Lactobacillus casei Shirota strain with global distribution in probiotic dairy and supplements. Comparable as a globally scaled, single-strain probiotic franchise, though delivery vehicle is primarily fermented dairy rather than supplements.
  • Danone (Essential Dairy & Plant-Based / Medical Nutrition): Global food and nutrition major with large probiotic and microbiome exposure (Activia, Actimel, medical nutrition brands). Comparable in end-market overlap (digestive health, women's health, infant nutrition) but operates at vastly larger scale and broader portfolio than Biocodex.
  • Bayer Consumer Health: Division of Bayer selling OTC pharma, probiotics, and women's health brands globally through pharmacy and mass retail. Comparable in target categories (women's health, gut health, OTC pharma) though it operates across a much broader portfolio and larger geographic footprint.
  • Sanofi Consumer Healthcare: French-headquartered global pharmaceutical major with a dedicated Consumer Healthcare business spanning women's health, digestive health, and probiotics. Comparable in target therapeutic areas and pharmacy-channel GTM, though at much larger scale and with broader R&D capabilities.

Regional players

  • Pierre Fabre: French privately held pharmaceutical and dermo-cosmetic group with strong pharmacy-channel presence in women's health, dermatology, and consumer health. Highly comparable as a French independent pharma peer with similar pharmacy distribution model, family-ownership heritage, and women's health focus.

Emerging players

  • Theranexus: French clinical-stage biotech developing treatments for rare neurological diseases including Batten-1 and TX01. Biocodex is its licensing partner and exclusive worldwide commercialization partner for these assets, making it a directly relevant biotech counterpart in the rare disease pipeline.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

BIOCODEX financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BIOCODEX leadership team

Management profile

Number of profiles

Profiles1 record

BIOCODEX subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

BIOCODEX funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BIOCODEX M&A and investment

M&A and investment

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BIOCODEX

What does BIOCODEX do?

Biocodex develops, manufactures, and commercializes pharmaceutical products, dietary supplements, medical devices, and dermo-cosmetics built on microbiome science. Its portfolio spans five therapeutic areas — microbiota, women's health, mental health, rare diseases, and family health/established products — distributed through pharmacy and parapharmacy networks, 16 subsidiaries, and 100+ distribution partners across more than 15 countries.

Is BIOCODEX a public or private company?

BIOCODEX is a private company. It is classified as family owned and is currently operating.

When was BIOCODEX founded?

BIOCODEX was founded in 1953. It employs 1,001 to 5,000 people.

Where is BIOCODEX based?

BIOCODEX is headquartered in Gentilly, France, in the Europe region.

How does BIOCODEX make money?

Four revenue lines are on record. Pharmaceutical products are the primary driver. The others are dietary supplements, medical devices and rare disease drug licensing.

Who are BIOCODEX's main competitors?

Direct peers on record are Novonesis (Chr. Hansen), BioGaia, Lallemand Health Solutions and Probi. Broad incumbents are Yakult Honsha, Danone (Essential Dairy & Plant-Based / Medical Nutrition), Bayer Consumer Health and Sanofi Consumer Healthcare. Pierre Fabre is listed as a regional player. Theranexus is listed as an emerging player.

Does BIOCODEX have an API?

No public API is recorded for BIOCODEX.

What industry is BIOCODEX in?

BIOCODEX's product category is Microbiota Pharmaceuticals. Its primary akta.pro industry code is HLAAAFAJ, Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery), with a secondary code of EUAAAIAK, Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MDPIMolecular Genetic Characterization of Commercial Probiotics Saccharomyces boulardii (Enterol®, Biocodex) and Baker’s (Cosm-O-tentic®, Puratos) YeastsThree S. boulardii strains from commercial probiotics were characterized for potential space-flight use. They show differences in nucleotide sequences, ploidy, MAL and CUP1 loci, and antifungal susceptibility. Copper and fungicide sensitivity are proposed as markers for future genetic-stability studies.News-MedicalMRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicinesMRM Health and Biocodex announced a strategic partnership to build specialized manufacturing for live biotherapeutics, with Biocodex investing €15 million in a new facility in Beauvais, France. The infrastructure will support MRM Health's lead candidate MH002 and other CORAL® programs, with process development and pilot manufacturing expected by 2027 and commercial-scale production targeted from 2030.Business Wire BlogBiocodex Invests €15 Million in a New Industrial Platform for Live Biotherapeutic ProductsBiocodex announced a €15 million investment to develop an industrial platform in Beauvais, France, for live biotherapeutic products derived from the microbiome. The platform will support partners and Biocodex's own programs from clinical batches to commercial production, with deployment starting in 2026 and first clinical batches in 2028.Business & FinancialMRM Health And Biocodex Establish Strategic Partnership To Strengthen Future Commercial Supply Capabilities For CORAL®-Based MedicinesMRM Health and Biocodex announced a strategic partnership to establish specialized manufacturing for live biotherapeutics, with Biocodex investing €15 million in anaerobic infrastructure in Beauvais, France. The facility will support MRM Health's lead candidate MH002 and other CORAL® programs, with process development expected by 2027 and commercial-scale manufacturing targeted from 2030.The Pharma LetterBiocodex invests in live biotherapeutic manufacturing for MRM Health’s microbiome drugsMRM Health and Biocodex launched a partnership to build live biotherapeutic manufacturing capacity, including for MRM's lead candidate MH002. Biocodex will invest 15 million euros over the coming years in new infrastructure at its Beauvais site.Business & FinancialMRM Health And Biocodex Establish Strategic Partnership To Strengthen Future Commercial Supply Capabilities For CORAL®-Based MedicinesMRM Health and Biocodex announced a strategic partnership to build specialized manufacturing for live biotherapeutics, with Biocodex investing €15 million in anaerobic infrastructure. The facility will support MRM Health's lead program MH002 and other CORAL® programs, with initial activities expected in 2027 and commercial-scale manufacturing targeted from 2030.Mirage NewsMRM Health, Biocodex Partner to Strengthen CORAL Drug Supply CapabilitiesMRM Health and Biocodex announced a partnership to build specialized manufacturing for live biotherapeutics, with Biocodex investing €15 million in anaerobic infrastructure in Beauvais, France. The facility will support MRM Health's lead candidate MH002 and other CORAL programs, with process development starting in 2027 and commercial-scale manufacturing targeted from 2030.Business & FinancialMRM Health And Biocodex Establish Strategic Partnership To Strengthen Future Commercial Supply Capabilities For CORAL®-Based MedicinesMRM Health and Biocodex announced a strategic partnership to establish specialized manufacturing for live biotherapeutics, with Biocodex investing €15 million in anaerobic infrastructure in Beauvais, France. The facility will support MRM Health's lead program MH002 and other CORAL® programs, with initial process development expected by 2027 and commercial-scale manufacturing targeted from 2030.GlobeNewswireMRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicinesMRM Health and Biocodex announced a strategic partnership to establish specialized manufacturing for live biotherapeutics, with Biocodex investing €15 million in anaerobic infrastructure in Beauvais, France. The facility will support MRM Health's lead program MH002 and other CORAL® programs, with initial process development expected by 2027 and commercial-scale manufacturing targeted from 2030.Journal quotidien La TribuneBiocodex investit 15 millions d'euros à Beauvais pour une usine unique en biothérapiesBiocodex announced a 15 million euro investment in its Beauvais plant to produce live biotherapeutic products from the microbiome. The company, which employs 1,900 people, will focus on reducing side effects of cancer treatments and other health applications. The project is subject to a public inquiry starting November 9.